Kami Nestler
Family · Wilkes Barre, PANPI 1346713716
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $103,063 of the $128,804 with a category attached, or 80.0%. AbbVie accounts for 74.1% of it on its own, with 14 other manufacturers making up the rest. 2024 is the largest year on record at $54,816, 4.8 times the $11,515 reported in 2021. Among family clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 538 payments — averaging $239.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$95K
- Teva Pharmaceuticals USA, Inc.$28K
- Johnson & Johnson$2K
- Neurocrine Biosciences, Inc.$995
- Otsuka America Pharmaceutical, Inc.$859
- Alkermes, Inc.$643
- plus $869 from 9 others
What the payments were for
- Speaking & faculty fees$103,06380%
- Travel & lodging$16,97513%
- Food & beverage$8,7677%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 181 | $95,463 |
| Teva Pharmaceuticals USA, Inc. | 176 | $28,005 |
| Johnson & Johnson | 47 | $1,969 |
| Neurocrine Biosciences, Inc. | 25 | $995 |
| Otsuka America Pharmaceutical, Inc. | 42 | $859 |
| Alkermes, Inc. | 31 | $643 |
| Axsome Therapeutics, Inc. | 9 | $281 |
| Vanda Pharmaceuticals Inc. | 11 | $276 |
| Indivior Inc. | 4 | $88 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $64 |
| Lundbeck LLC | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Sunovion Pharmaceuticals Inc. | 2 | $33 |
| Gilead | 1 | $23 |
| Almatica Pharma LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$92,877
- UZEDY$24,817
- SPRAVATO$636
- INGREZZA$593
- XARELTO$500
- LYBALVI$480
- Austedo XR$363
- INVEGA SUSTENNA$125
- INVEGA TRINZA$125
- Auvelity$125
- Fanapt$125
How this compares
$128,804 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UzedyRisperidone | 60 | $303,545 |
| VraylarCariprazine Hcl | 132 | $172,245 |
| Invega TrinzaPaliperidone Palmitate | 16 | $139,168 |
| Invega SustennaPaliperidone Palmitate | 39 | $107,405 |
| LybalviOlanzapine/Samidorphan Malate | 39 | $62,417 |
| TrintellixVortioxetine Hydrobromide | 36 | $21,384 |
| RexultiBrexpiprazole | 14 | $21,356 |
| Risperidone ErRisperidone Microspheres | 24 | $10,939 |
| Clozapine | 146 | $9,463 |
| Paliperidone ErPaliperidone | 38 | $9,185 |
| RisperdalRisperidone | 18 | $9,153 |
| Divalproex Sodium ErDivalproex Sodium | 123 | $7,442 |
| Buspirone Hcl | 289 | $5,413 |
| Aripiprazole | 138 | $4,129 |
| Quetiapine Fumarate | 268 | $4,038 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Uzedy | $28,005 | $303,54560 claims |
| Johnson & JohnsonInvega Trinza, Invega Sustenna, Risperdal | $1,969 | $255,72673 claims |
| AbbVieVraylar | $95,463 | $172,245132 claims |
| Alkermes, Inc.Lybalvi | $643 | $62,41739 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $33 | $21,38436 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $859 | $21,35614 claims |
| Almatica Pharma LLCSertraline Hcl | $20 | $2,175224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.
Other family in Wilkes Barre
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
- Patricia HabdasPittsburgh$83K
- Anne CalvaresiPhiladelphia$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.